Biocon Q1 FY27 Results: Revenue Up 10%, PAT +53%

Results snapshot and why it matters

Biocon reported a steady operating quarter in Q1 FY27, with year-on-year growth in revenue and a sharper improvement in profitability. The company said the performance was led by its Biosimilars and Generics businesses, even as revenue and operating margin moderated sequentially. Biocon announced the results on August 5, 2026 for the quarter ended June 30, 2026. The numbers also come soon after a structural change, with Biocon Biologics Limited (BBL) becoming a wholly owned subsidiary effective June 29, 2026.

Headline financials: revenue up, profit higher

Revenue from operations rose 10.00% year-on-year to ₹4,336 crore in Q1 FY27 versus ₹3,942 crore in Q1 FY26. Total revenue increased 9.17% year-on-year to ₹4,391 crore compared with ₹4,022 crore in the year-ago quarter. Profit after tax (PAT) was reported at ₹137 crore, up from ₹89 crore in Q1 FY26, implying a 53.36% year-on-year increase. Separately, profit after tax attributable to owners of the company was reported at ₹141 crore, compared with ₹31 crore a year earlier, a 349.36% rise. The company also disclosed net profit before exceptional items of ₹145 crore and net profit after exceptional items of ₹141 crore.

Operating profitability and margins

Biocon reported an EBITDA margin of 19.54% for the quarter. In another disclosure set, consolidated EBITDA was stated at ₹902 crore with a margin of 21%. PAT margin stood at 3.15%, compared with 2.26% in Q1 FY26 and 4.40% in Q4 FY26. That indicates a year-on-year improvement of 0.89 percentage points, but a sequential decline of 1.24 percentage points. EPS for the quarter was ₹0.87, compared with ₹0.26 in Q1 FY26 and ₹0.79 in Q4 FY26.

QoQ picture: sequential pressure in revenue and EBITDA

On a sequential basis, revenue from operations declined 4.00% to ₹4,336 crore from ₹4,517 crore in Q4 FY26. Total revenue fell 3.91% to ₹4,391 crore from ₹4,569 crore in the prior quarter. EBITDA (excluding other income) was ₹847 crore, down 16.97% quarter-on-quarter from ₹1,020 crore. The sequential movement underlines that the quarter saw softer operating performance versus Q4 FY26, even while year-on-year growth remained intact. Management commentary in the data provided linked the overall year-on-year improvement in profitability to better performance in core businesses and reduced finance costs.

Segment performance: Biosimilars stayed the largest contributor

Biocon reported mixed segment performance in Q1 FY27, with growth in Biosimilars and Generics but weakness in Services. Biosimilars revenue was ₹2,855.6 crore, up 16.19% year-on-year and 3.63% sequentially, making it the largest contributor to overall revenue. Generics revenue was ₹759.7 crore, up 20.53% year-on-year but down 2.10% quarter-on-quarter. Services revenue was ₹736.0 crore, down 15.84% year-on-year and 28.99% sequentially. In a separate disclosure set, the Generics segment reported a loss before tax of ₹30.9 crore, while Services reported a loss before tax of ₹5.7 crore.

Key financial metrics table (consolidated)

Segment revenue table

Finance costs, exceptional items, and balance sheet actions

Biocon reported that interest costs reduced 23% year-on-year to ₹213 crore, reflecting measures taken to strengthen the balance sheet. The company also disclosed consolidated exceptional items (net) of -₹13.5 crore for the quarter. These line items are relevant because they help explain the gap between operating performance and the sharper improvement seen in reported net profit measures. Biocon’s disclosures also separately listed standalone numbers, including total income of ₹689.3 crore and standalone PAT of ₹52.2 crore.

Corporate actions and group structure updates

BBL became a wholly owned subsidiary on June 29, 2026 through a share swap transaction, a change that the company indicated will allow 100% of BBL’s profit to accrue to Biocon shareholders. The Board recommended a final dividend of ₹0.50 per equity share, subject to shareholder approval. Separately, Syngene’s subsidiary, Syngene Manufacturing Limited, entered voluntary liquidation and the process was stated as ongoing. The financial results were approved by the Board at a meeting held on August 5, 2026, and the statements underwent a limited review by statutory auditors.

Stock market reaction and recent returns

Biocon shares closed 0.76% higher on August 5, 2026 after the results. Another disclosure noted the stock closed at ₹425.20 on the NSE that day. The stock has delivered 10% returns year-to-date and 14% over the one year period from August 5, 2025 to August 5, 2026. A separate market snapshot listed a market capitalisation of ₹69,579.79 crore and a CMP of ₹426.95.

What investors will track next

Biocon is scheduled to host an earnings call on August 6, 2026, to discuss Q1 performance and take investor questions. Investors are likely to focus on how the company sustains biosimilars momentum, given biosimilars remained the largest revenue driver in the quarter. Attention may also stay on the services segment trajectory, which saw a sharp sequential decline in revenue. Disclosures also mentioned approvals in Canada and the launch of Yesafili in the US, which the company indicated provide visibility for biosimilar streams in coming quarters.

Conclusion

Biocon’s Q1 FY27 results showed stable top-line growth year-on-year, led by biosimilars and generics, alongside a significant improvement in reported profits and EPS. The quarter also reflected sequential pressure in revenue and EBITDA (excluding other income), while finance costs fell meaningfully. Key corporate updates included BBL becoming a wholly owned subsidiary and a final dividend recommendation of ₹0.50 per share. The next near-term checkpoint is the earnings call scheduled for August 6, 2026.